Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPotential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy
Clinical Pharmacology & Therapeutics, 07/02/09
You JHS et al. - Genotype-guided dosing for warfarin therapy does not appear to be cost-effective, with the potential ICER per QALY being >$50,000. Lowering the genotyping cost, improving effectiveness of INR control of the genotype-guided dosing algorithm, and applying the algorithm in practice sites with high out-of-range INRs would improve the cost-effectiveness of the dosing algorithm.
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Nephroprotective Effect of Withania somnifera: A Dose-Dependent Study
Renal Failure, 11/30/09
Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir
Annals of Pharmacotherapy, 11/25/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
PharmacoEconomics, 11/30/09
Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
PharmacoEconomics, 11/24/09
Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09
Sponsor
Article Search
Sponsor